Barriers to inhaled gene therapy of obstructive lung diseases: A review
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Knowledge of genetic origins of obstructive lung diseases has made inhaled gene therapy an attractive alternative to the current standards of care that are limited to managing disease symptoms. Initial lung gene therapy clinical trials occurred in the early 1990s following the discovery of the genetic defect responsible for cystic fibrosis (CF), a monogenic disorder. However, despite over two decades of intensive effort, gene therapy has yet to help patients with CF or any other obstructive lung disease. The slow progress is due in part to poor understanding of the biological barriers to inhaled gene therapy. Encouragingly, clinical trials have shown that inhaled gene therapy with various viral vectors and non-viral gene vectors is well tolerated by patients, and continued research has provided valuable lessons and resources that may lead to future success of this therapeutic strategy. In this review, we first introduce representative obstructive lung diseases and examine limitations of currently available therapeutic options. We then review key components for successful execution of inhaled gene therapy, including gene delivery systems, primary physiological barriers and strategies to overcome them, and advances in preclinical disease models with which the most promising systems may be identified for human clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 1×
“Lipid- and Polymer-based Facile chemical modification [137] Minimal constraint in packaging capacity [151, 184] Large-scale production [186] Variety of FDA-approved drug delivery formulations [187] Controlled release is achievable [139] Cytotoxicity [153, 173] No intrinsic tropism [139] (Lipid) Occasional stability is…”
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Self-citationNon-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · cited 2×
“Lipid- and Polymer-based Facile chemical modification [137] Minimal constraint in packaging capacity [151, 184] Large-scale production [186] Variety of FDA-approved drug delivery formulations [187] Controlled release is achievable [139] Cytotoxicity [153, 173] No intrinsic tropism [139] (Lipid) Occasional stability is…”
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501 · cited 2×
“Another limitation of retroviral vectors is their inability to infect non-dividing cells [121], which limits their use for inhaled gene therapy applications given the slow turnover rate of airway epithelium [7].”
Nonviral vectors for gene delivery
Mintzer, M. A., & Simanek, E. E. (2009) · Chemical Reviews · doi:10.1021/cr800409e · Cited by 2,366 · cited 1×
“Lipid- and Polymer-based Facile chemical modification [137] Minimal constraint in packaging capacity [151, 184] Large-scale production [186] Variety of FDA-approved drug delivery formulations [187] Controlled release is achievable [139] Cytotoxicity [153, 173] No intrinsic tropism [139] (Lipid) Occasional stability is…”
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195 · cited 1×
“Ivacaftor demonstrated significant improvements in lung function of CF patients [24, 25].”
Growing Self-Organizing Mini-Guts from a Single Intestinal Stem Cell: Mechanism and Applications
Sato, T., & Clevers, H. (2013) · Science · doi:10.1126/science.1234852 · Cited by 1,170 · cited 1×
“Primary human organoids differentiated from patient-derived stem cells are also an attractive in vitro model for high-throughput screening [434].”
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088 · cited 2×
“Another drug, lumacaftor (VX-809), showed promising in vitro correction of the most prevalent CFTR mutation, ΔF508, which represents ~70% of CF patients [26].”
A functional CFTR assay using primary cystic fibrosis intestinal organoids
Dekkers, J. F., Wiegerinck, C. L., de Jonge, H. R., Bronsveld, I., Janssens, H. M., de Winter-de Groot, K. M., Brandsma, A. M., de Jong, N. W. M., Bijvelds, M. J. C., Scholte, B. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3201 · Cited by 999 · cited 1×
“Specifically for CF, the organoid’s degree of swelling in response to the treatment with a well-documented CFTR activator, forskolin, was found to correlate with CFTR function, providing a means to assess CFTR activity and/or correction [435].”
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“AAV is a non-enveloped, icosahedral, non-replicating capsid virus with a diameter of roughly 25 nm [97].”
Cited by
Schneider, C. S., Xu, Q., Boylan, N. J., Chisholm, J., Tang, B. C., Schuster, B. S., Henning, A., Ensign, L. M., Lee, E., Adstamongkonkul, P., et al. (2017) · Science Advances · doi:10.1126/sciadv.1601556 · Cited by 311
Self-citationProtein nanocages that penetrate airway mucus and tumor tissue
Huang, X., Chisholm, J., Zhuang, J., Xiao, Y., Duncan, G., Chen, X., Suk, J. S., & Hanes, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705407114 · Cited by 131
“One of the primary barriers to effective inhalation of therapeutics to the lung airways is the protective mucus gel layer lining the airway epithelium (15, 16).”
BackgroundSelf-citationGuan, S., Munder, A., Hedtfeld, S., Braubach, P., Glage, S., Zhang, L., Lienenklaus, S., Schultze, A., Hasenpusch, G., Garrels, W., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0358-x · Cited by 130
Zhu, J., Guo, M., Cui, Y., Meng, Y., Ding, J., Zeng, W., & Zhou, W. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c23069 · Cited by 46
Genetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
Metadata
- Authors
- Kim, N., Duncan, G. A., Hanes, J., & Suk, J. S.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 240
- Pages
- 465-488
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2397508962
- Cited by
- 118
- References
- 31
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.